Molecule News and Research

RSS

Research and movement in future towards universal influenza virus vaccine

Researchers at Mt. Sinai School of Medicine have developed a novel influenza vaccine that could represent the next step towards a universal influenza vaccine eliminating the need for seasonal immunizations. They report their findings today in the inaugural issue of mBio-, the first online, open-access journal published by the American Society for Microbiology.

20 May 2010

New study uses NMR in drug design

A new study by a team of researchers led by Jeffrey Peng, assistant professor of chemistry and biochemistry at the University of Notre Dame, is using Nuclear Magnetic Resonance, to move drug design into groundbreaking consideration of the dynamic flexibility of drugs and their targets.

20 May 2010

Boston University biomedical engineers develop new nanopore method for DNA sequencing

Sequencing DNA could get a lot faster and cheaper - and thus closer to routine use in clinical diagnostics - thanks to a new method developed by a research team based at Boston University. The team has demonstrated the first use of solid state nanopores - tiny holes in silicon chips that detect DNA molecules as they pass through the pore - to read the identity of the four nucleotides that encode each DNA molecule.

20 May 2010

Curis announces inclusion in NASDAQ Biotechnology Index

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index (NBI), which will become effective prior to market open on Monday, May 24, 2010.

19 May 2010

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Targacept, Inc., a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has initiated a Phase 2 clinical proof of concept trial of TC-5619 in adults with attention deficit/hyperactivity disorder (ADHD). TC-5619 is a novel small molecule that is highly selective for the alpha7 neuronal nicotinic receptor, which Targacept refers to as NNR, and was discovered by Targacept scientists using Targacept's proprietary drug discovery platform known as Pentad (TM).

19 May 2010

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and ophthalmology, announced today that results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 will be presented at the annual meeting of the American Society of Clinical Oncology on June 5-7, 2010 in Chicago, IL.

19 May 2010

Experimental evolution used to develop new strains of bacteria for use as probiotic substances

When the forces of evolution took over an experimental strain of bacteria, it derailed an experiment Duke and NC State researchers thought they were conducting, but led to something much more profound instead.

19 May 2010

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Geron Corporation today announced positive data on its orally available small molecule telomerase activator, TAT153, in an animal model of idiopathic pulmonary fibrosis (IPF). The data show that administration of TAT153 increased telomerase activity in the lung tissue, reduced inflammation, preserved functional lung tissue, slowed disease progression and attenuated loss of pulmonary function.

19 May 2010

Natural molecule in body counters progression of osteoarthritis: Scientists

An international team of scientists from The Scripps Research Institute in California and the National Research Institute for Child Health and Development in Japan has discovered that a natural molecule in the body counters the progression of osteoarthritis. The findings could one day lead to new therapies for some common diseases of aging.

19 May 2010

PET scanning provides great insight into immune response

A commonly used probe for Positron Emission Tomography scanning and a new probe developed by researchers at UCLA reveal different functions in diverse cells of the immune system, providing a non-invasive and much clearer picture of an immune response in action.

19 May 2010

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Vect-Horus is a biotechnology company based on the scientific work of Dr. Michel Khrestchatisky and specializes in the development of peptide and pseudo-peptide-based vector molecules for drug targeting and delivery to the central nervous system (CNS).

18 May 2010

Helicos BioSciences to focus business on diagnostics markets

Helicos BioSciences Corporation announced today that, as part of the Company's previously disclosed efforts to consider alternatives to its existing long-term strategy, it is in the process of implementing a strategic shift to focus the business on the diagnostics markets. In connection with this effort, the Company has committed to a consolidation and reorganization of its operations in order to reduce operating costs.

18 May 2010

University of Leeds researchers identify natural defence mechanism against heart disease

A natural defence mechanism against heart disease could be switched on by steroids sold as health supplements, according to researchers at the University of Leeds.

18 May 2010

Population Diagnostics receives NINDS grant for identifying genetic causes of Parkinson's Disease

Population Diagnostics, Inc. ("PDx"), a private company with a novel approach to revealing the genetic causes of disease and predicting drug response, announced today it has been awarded a federal grant to identify the genetic causes of Parkinson's Disease. Funded by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health, the project is being led by Eli Hatchwell, MD, PhD, an Associate Professor at Stony Brook University Medical Center and a co-founder of PDx.

18 May 2010

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

Celldex Therapeutics, Inc. today announced that the first patient has been screened in a randomized Phase 2 study of the Company's novel, first-in-class antibody-based vaccine candidate from its Precision Targeted Immunotherapy (PTI) platform. This study will evaluate the CDX-1307 regimen in both neoadjuvant and adjuvant settings in patients with newly diagnosed muscle-invasive bladder cancers that express hCG-beta.

17 May 2010

Scientists find clues to how our brains work

Scientists from The Scripps Research Institute have found a specific chemical compound secreted by many predators that makes mice behave fearfully. The research helps scientists better understand animal behavior, and may eventually lead to new insights into how sensory information is processed in human brains.

17 May 2010

Computerized model for treating nicotine addiction wins first place at ISEF science competition

A project using cutting edge computer modeling to identify potential new medications for nicotine addiction won first place distinction at the annual Addiction Science Awards at this year's Intel International Science and Engineering Fair (ISEF) --- the world's largest science competition for high school students.

15 May 2010

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Hana Biosciences Inc.,, a biopharmaceutical company focused on strengthening the foundation of cancer care, today reported financial results for the first quarter ended March 31, 2010, and provided a corporate update.

14 May 2010

Researchers determine how cells regulate chromosome/microtubule interface

Whitehead Institute researchers have determined a key part of how cells regulate the chromosome/microtubule interface, which is central to proper chromosomal distribution during cell division.

14 May 2010

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Novel vaccines for diseases ranging from the flu to HIV highlight a week's worth of biotechnology research at the American Association of Pharmaceutical Scientists' National Biotechnology Conference. Scientists from academia, industry, and government will gather at the Hilton San Francisco Union Square Sunday, May 16 -Thursday, May 20 to share research and advances in biotherapeutics.

14 May 2010

Molecule News and Research

Research and movement in future towards universal influenza virus vaccine

New study uses NMR in drug design

Boston University biomedical engineers develop new nanopore method for DNA sequencing

Curis announces inclusion in NASDAQ Biotechnology Index

Targacept commences Phase 2 clinical proof of concept trial of TC-5619 in adults with ADHD

Results from Phase 1 clinical trials of TRC105, TRC102, and TRC093 to be presented at ASCO 2010

Experimental evolution used to develop new strains of bacteria for use as probiotic substances

Positive data from Geron's TAT153 small molecule telomerase activator in animal model of IPF

Natural molecule in body counters progression of osteoarthritis: Scientists

PET scanning provides great insight into immune response

Vect-Horus accentuates its leadership in delivering drugs to the central nervous system

Helicos BioSciences to focus business on diagnostics markets

University of Leeds researchers identify natural defence mechanism against heart disease

Population Diagnostics receives NINDS grant for identifying genetic causes of Parkinson's Disease

Celldex Therapeutics commences screening in CDX-1307 Phase 2 study for bladder cancer

Scientists find clues to how our brains work

Computerized model for treating nicotine addiction wins first place at ISEF science competition

Hana Biosciences reports $5.5 million net loss for first-quarter 2010

Researchers determine how cells regulate chromosome/microtubule interface

Novel vaccines for deadly diseases to be presented at AAPS' NBC

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News